Heart failure (HF) is a rapidly growing public health issue with an estimated prevalence of >37.7 million individuals globally. HF is a shared chronic phase of cardiac functional impairment secondary to many aetiologies, and patients with HF experience a range of symptoms that affect their quality of life, including dyspnoea, fatigue, poor exercise tolerance and fluid retention.

The burden of HF will continue to rise, due to population aging, population growth and improved treatment of HF and other cardiovascular disorders. As a result, clinicians will be increasingly challenged to develop treatment plans and care systems that reduce the high levels of morbidity and mortality experienced by these patients, both from their HF and other comorbidities.


The Role of p53 Localised in Cytosol and Mitochondria During Reprogramming to iPS Cells


European Cardiology Review 2018;13(2):127.

TBL1 Suppresses Cardiomyocyte Hypertrophy by Regulating the Interaction Between HDAC3 and GATA4


European Cardiology Review 2018;13(2):126.

The GATA4 Acetylation Site Plays a Key Role in the Development of Cardiomyocyte Hypertrophy


European Cardiology Review 2018;13(2):125.

Analysis of the Effects of EPA and DHA on Cardiomyocyte hypertrophy


European Cardiology Review 2018;13(2):121.